Beatriz Mínguez - Concepedia

Author

Beatriz Mínguez

Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas ORCID

Also Known As

B. Minguez, B. Mínguez, Beatriz Minguez, Beatriz Minguez Rosique, Beatriz Mínguez, Beatriz Mínguez Rosique, Léa Bruges, Ward, Stephen C.

144

Publications

7.6K

Citations

H-Index

Concepts

All Affiliations

Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas Universitat Autònoma de Barcelona Vall d'Hebron Institut de Recerca Universitat de Barcelona Vall d'Hebron Hospital Universitari

About

Beatriz Mínguez is an author at Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas specializing in medicine, hepatology, and hepatocellular carcinoma.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	22	27	3.5K
2	Health Sciences	7	7	876
3	Engineering	1	1	59
4	Public Health	1	1	10
5	Cardiothoracic Surgery	1	1	10

Beatriz Mínguez

Publications

6.4K

Citations

H-Index

Page 1

	Year	Citations
Pivotal Role of mTOR Signaling in Hepatocellular Carcinoma Augusto Villanueva, Derek Y. Chiang, Pippa Newell, Gastroenterology	2008	722
Focal Gains of <i>VEGFA</i> and Molecular Classification of Hepatocellular Carcinoma Derek Y. Chiang, Augusto Villanueva, Yujin Hoshida, Cancer Research	2008	693
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial Shukui Qin, Minshan Chen, Ann‐Lii Cheng, The Lancet Surgical OncologyHepatologyMedicinePathologyHigh-risk Hepatocellular Carcinoma	2023	415
Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial Josep M. Llovet, Masatoshi Kudo, Philippe Merle, The Lancet Oncology OncologyHepatologyMedicineClinical TrialsPembrolizumab Versus Lenvatinib	2023	364
Wnt-Pathway Activation in Two Molecular Classes of Hepatocellular Carcinoma and Experimental Modulation by Sorafenib Anja Lachenmayer, Clara Alsinet, Radoslav Savić, Clinical Cancer Research	2012	296
Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma Robert Montal, Daniela Sia, Carla Montironi, Journal of Hepatology Tumor BiologyHepatologyMedicineHepatobiliary TumorBiliary Cancer	2020	274
MicroRNA-Based Classification of Hepatocellular Carcinoma and Oncogenic Role of miR-517a Sara Toffanin, Yujin Hoshida, Anja Lachenmayer, Gastroenterology	2011	232
Prognostic Gene Expression Signature for Patients With Hepatitis C–Related Early-Stage Cirrhosis Yujin Hoshida, Augusto Villanueva, Angelo Sangiovanni, Gastroenterology Autoimmune DiseaseHepatitis CHepatologyViral HepatitisLiver Physiology	2013	224
IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage Victoria Tovar, Clara Alsinet, Augusto Villanueva, Journal of Hepatology HepatologyIgf-1r BlockageLiver PhysiologyPathologyLiver Cancer	2010	220
Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo Pippa Newell, Sara Toffanin, Augusto Villanueva, Journal of Hepatology Hepatocellular CarcinomaMedicineAnti-tumoral EffectRas Pathway ActivationPathology	2009	219

Page 1